HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO) on Thursday reported fourth-quarter net income of $720 million, after reporting a loss in the same period a year earlier ...
Bio-Rad remains undervalued, but persistent end-market headwinds and limited core growth drivers temper my conviction. BIO's valuation is heavily influenced by its substantial Sartorius stake, and the ...
Some batteries that power a popular brand of e-bike pose a fire hazard that can cause serious injury or death and shouldn't be used, the Consumer Product Safety Commission (CPSC) said in a notice ...
The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low. Bio-Rad's Q3 saw the company book ...
Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The third quarter was a strong one for the fund ...
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, and Gencurix, Inc., a leading Korean developer of oncology testing solutions, today announced ...
Bio-Rad Laboratories, Inc. (NYSE:BIO) ranks among the best medical stocks to buy according to analysts. On July 31, Bio-Rad Laboratories, Inc. (NYSE:BIO) posted second-quarter earnings that far ...
Bio-Rad Laboratories, Inc. (NYSE:BIO) reported better-than-expected second-quarter financial results on Thursday. Bio-Rad Laboratories reported quarterly earnings of $2.61 per share which beat the ...
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results